WLWenqiang Li

Wenqiang Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wenqiang Li has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    From Microbiome Modulation to Novel Therapeutics: Recent Advances in Therapeutic Strategies for Gastrointestinal Cancers

    by Sinhang Cheng, Yin Zhang, Wenqiang Li, Guoshuai Xu, Jun Qu

    The gut microbiome has emerged as a key modulator of therapeutic responses in gastrointestinal cancers. This narrative review critically summarizes how specific pathogenic bacteria—including Fusobacterium nucleatum, Bacteroides fragilis, and Gammaproteobacteria—have been implicated in chemoresistance through autophagy activation, suppression of endoplasmic reticulum stress-mediated cell death, inhibition of pyroptosis, induction of cancer-cell quiescence, and direct drug metabolism. In immunotherapy, the microbiome profoundly influences immune checkpoint inhibitor efficacy; Akkermansia muciniphila and Clostridium butyricum enhance anti-tumor immunity via the cGAS-STING pathway and the secD/GRP78/IL-6 axis, while microbial metabolites such as succinate, 4-hydroxyphenylacetic acid, and spatially depleted butyrate promote resistance through CD8+ T-cell exhaustion and immunosuppressive cell recruitment. In gastric cancer, Helicobacter pylori and non-Helicobacter gastric microbiota shape chemotherapy and immunotherapy responses; in hepatocellular carcinoma, the gut–liver axis and bile acid metabolism influence immune checkpoint blockade; and in pancreatic ductal adenocarcinoma, intratumoral Gammaproteobacteria and metabolites such as trimethylamine N-oxide and indole-3-acetic acid modulate gemcitabine resistance and immunotherapy efficacy. We further evaluate emerging microbiome-targeted strategies including fecal microbiota transplantation, engineered probiotics, and bacteriophage therapy, and discuss challenges in clinical translation. By elucidating the molecular mechanisms of microbiome-mediated therapy modulation, we propose a hypothesis-generating, evidence-graded framework for future prospective validation in microbiome-guided precision oncology.

  • Open Access

    High sensitivity‑C‑reactive protein variability and risk of cancer incidence: A longitudinal prospective cohort study cancer

    by Guoshuai Xu, Renjia Cheng, Yiming Wang, Xiangming Ma, Qingsong Zhang, Jun Qu, Wenqiang Li

    The association between inflammation and cancer has been extensively studied. However, studies examining the relationship between the magnitude of inflammatory fluctuations and cancer remain limited. Consequently, the present study aimed to explore the association between high‑sensitivity C‑reactive protein (hs‑CRP) variability and the occurrence of cancer. A total of 42,514 participants were enrolled in the present study, with their hs‑CRP levels measured over a 4‑year period. The coefficient of variation (CV) of hs‑CRP was used to quantify the variability in inflammatory status. Cox regression analysis was used to assess the association between hs‑CRP variability and cancer risk after adjusting for potential confounding factors. The results demonstrated that a high CV of hs‑CRP was significantly associated with reduced cancer risk [hazard ratio (HR), 0.84; 95% confidence interval (CI), 0.75‑0.94]. Participants with high hs‑CRP and low CV had a significantly increased risk of cancer (HR, 1.42; 95% CI, 1.18‑1.70). In the stratified analysis of tumors at different sites, the association between hs‑CRP variability and lung cancer risk was the most pronounced (HR, 0.77; 95% CI, 0.63‑0.96). Sensitivity analyses confirmed the stability of the association between hs‑CRP variability and cancer. In conclusion, higher hs‑CRP variability was associated with lower cancer risk, particularly for lung cancer; however, these findings provide preliminary evidence and require validation in future studies.

  • Open Access

    Organ preservation after neoadjuvant immunotherapy in mismatch repair-deficient colorectal cancer: response assessment, watch-and-wait, and salvage surgery

    by Nan Yao, Guoshuai Xu, Ning Duan, Fuzhou Han, Wenqiang Li, Jun Qu

    Neoadjuvant immune checkpoint blockade has produced high pathological and clinical response rates in mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer, raising the possibility of response-adapted organ preservation. However, the evidence is anatomically uneven and remains immature for routine surgery avoidance. In dMMR colon cancer, neoadjuvant studies primarily establish drug activity through resection-confirmed pathological and nodal response; reliable criteria for nonoperative assessment have not been validated. In dMMR rectal cancer, clinical complete response (cCR) after PD-1 blockade may support watch-and-wait in highly selected patients because local response can be reassessed using digital rectal examination, endoscopy, pelvic MRI, biopsy when appropriate, systemic imaging, and tumor markers. This narrative review critically appraises the biological rationale, prospective and observational evidence, response-assessment limitations, surgical decision points, surveillance requirements, toxicity, and unresolved controversies surrounding organ preservation after neoadjuvant immunotherapy. We use the term immune-response-adapted surgical deferral to emphasize that surgery remains available for incomplete response, unresolved uncertainty, or regrowth. Current implementation should be confined to experienced multidisciplinary programs with rigorous molecular confirmation, standardized multimodal assessment, reliable follow-up, informed patient participation, and timely salvage capacity. Particular attention is given to immunotherapy-specific uncertainty in defining durable cCR, the limitations of circulating tumor DNA (ctDNA) as a stand-alone local decision tool, hereditary-risk considerations in Lynch syndrome, and the need for location-specific prospective validation.

  • Open Access

    Development and explanation of a machine learning model for identifying non-localized early-onset T1 colorectal cancer

    by Yin Zhang, Fuzhou Han, Mingyu Zheng, Duo Xu, Nan Yao, Wenqiang Li, Jun Qu

    Background For patients with early-onset T1 colorectal cancer (CRC), it is crucial to perform radical resection with minimal tissue damage. This study aims to develop and elucidate a machine learning model for the identification of non-located early-onset T1 CRC. Methods We extracted relevant data from the Surveillance, Epidemiology, and End Results (SEER) database and randomly allocated patients into a training set and a validation set. Five machine learning models were utilized: extreme gradient boosting (XGBoost), support vector machine (SVM), random forest (RF), decision tree (DT), and logistic regression (LR) were developed for the tumor metastasis status prediction. Area under the receiver operating characteristic curve (AUC) and confusion matrix were used to evaluate the model. The Shapley Additive Explanations (SHAP) method was employed as the primary technique for model explanation. Results A cohort of 1,878 patients was selected according to predefined inclusion and exclusion criteria. The XGBoost model was selected for its favorable performance, with an AUC of 0.755 and accuracy of 0.833 in the validation cohort. Significant risk factors, identified by SHAP values greater than 0.1 for non-localized T1 tumors, included carcinoembryonic antigen (CEA) levels exceeding 5 ng/mL, tumor size greater than 5 cm, mucinous adenocarcinoma, signet-ring cell adenocarcinoma, tumor location in the left colon, and poorly differentiated or undifferentiated histological grades. Additionally, black race, a diagnostic-to-surgical interval exceeding one month and PNI may represent potential risk factors. Conclusion The XGBoost model holds the potential to assist clinicians in evaluating and selecting optimal treatment strategies for patients with early-onset T1 CRC.


  • Open Access

    Bacteria into bloodstream caused by oral probiotics based on whole genome sequencing: A case report

    by Tianqi Qi, Yingshi Mm Wang, Yanhui Mm Liu, Wenqiang Li, Shanshan Wu

    Rationale: Bacillus licheniformis and Lactiplantibacillus plantarum are facultative anaerobes and gram-positive bacteria. They are commonly included in probiotic preparations and are administered orally in clinical practice to promote a balanced gut microbiota. Patient concerns: An 85-year-old man with irritable bowel syndrome and reflux esophagitis underwent distal pancreatectomy and was administered oral probiotics. Blood culture was positive for B. licheniformis and L. plantarum. We conducted whole-genome sequencing for homology analysis and pathogenicity prediction of the strains isolated from the patient’s blood culture and oral probiotics. Diagnosis: The initial diagnosis was bacterial entry into the bloodstream resulting from the consumption of B. licheniformis and L. plantarum probiotic preparations. Interventions: The patient was treated with discontinuation of oral probiotics and timely administration of antibiotics. Outcomes: Follow-up blood culture results after treatment were negative. Lessons: Probiotics are generally considered relatively safe but should be preceded by risk screening in vulnerable populations. Whole-genome sequencing revealed the potential risks of probiotic use through homology analysis and prediction of virulence factors and antibiotic resistance.


  • Open Access

    Exploring the landscape of drug resistance in gastrointestinal cancer immunotherapy: A review

    by Nan Yao, Wenqiang Li, Ning Duan, Guoshuai Xu, Guoyong Yu, Jun Qu

    Gastrointestinal (GI) cancers pose a significant challenge due to high prevalence and mortality. While advancements in detection and conventional treatments have been made, prognosis often remains poor, particularly for advanced-stage cancers. Immunotherapy has emerged as a transformative approach, leveraging the body immune system against cancer, including immune checkpoint inhibitors (ICIs), cancer vaccines, and adoptive cell transfer. These modalities have shown promise, achieving sustained responses and improved survival in some patients. However, their efficacy in GI cancers is less pronounced, hindered by drug resistance mechanisms that are either intrinsic or acquired over time. This review examines the latest understanding of immunotherapy in GI cancers, focusing on ICIs, cancer vaccines, and adoptive cell transfer, along with their associated outcomes and limitations. It delves into the mechanisms behind drug resistance, including alterations in immune checkpoints, the immunosuppressive tumor microenvironment, and genetic/epigenetic changes. The role of the gut microbiome is also considered as an emerging factor in resistance. To combat drug resistance, strategies such as enhancing immune response, targeting the tumor microenvironment, and modulating resistance mechanisms are explored. The review underscores the potential of ferroptosis induction as a novel approach. Looking forward, it highlights the need for personalized immunotherapies, understanding the influence of the gut microbiome, and further exploration of ferroptosis in overcoming resistance. While challenges persist, the continuous evolution in GI cancer immunotherapy research promises innovative treatments that could significantly improve patient outcomes.


  • Open Access

    Causal association between telomere length and colorectal polyps: A bidirectional two-sample Mendelian randomization study

    by Yin Zhang, Jiaying Mm Wang, Mingyu Mm Zheng, Huanwei Mm Qu, Shuya Mm Yang, Fuzhou Mm Han, Nan Mm Yao, Wenqiang Mm Li, Jun Qu

    We performed a bidirectional 2-sample Mendelian randomization (MR) design to explore the causal relation between telomere length (TL) and colorectal polyps. Genome-wide association study summary data of TL and colorectal polyps were extracted from the IEU open genome-wide association study database. Single nucleotide polymorphisms were served as instrumental variables at the significance threshold of P < 5 × 10−8. The inverse variance weighted method, MR-Egger method, and weight median method were performed for causal estimation in MR. Cochran Q test, MR-Egger intercept test, and leave-one-out analyses were performed to evaluate the pleiotropy of the MR results. One hundred and twenty-four single nucleotide polymorphisms were selected as instrumental variables. We found significant casual association between TL and colorectal polyps. Long TL increased the risk of colorectal polyps using the inverse variance weighted method [ukb-a-521: odds ratio (OR): 1.004, 95% confidence interval (CI): 1.001–1.007, P = .004; ukb-d-D12: OR: 1.008, CI: 1.004–1.012, P < .001; finn-b-CD2_BENIGN_COLORECANI_EXALLC2: OR: 1.170, CI: 1.027–1.332, P = .018]. Sensitivity analyses validated that the causality between TL and colorectal polyps was robust. The study provided a causal association between TL and colorectal polyps which indicated that TL might be served as a potential biomarker of colorectal polyps for screening and prevention. Nonetheless, the conclusions need further validation.